Sagimet Biosciences, Inc. Class A's total assets for Q1 2025 were $146.17M, a decrease of -8.79% from the previous quarter. SGMT total liabilities were $7.18M for the fiscal quarter, a 61.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.